Celsion Submits Clinical Protocol to The FDA For its GEN-1 Immunotherapy
News
Celsion Corporation has announced the submission of its Phase I clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, a DNA-based immunotherapy for cancer treatment. The protocol ... Read more